{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:57:36Z","timestamp":1785473856873,"version":"3.56.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100022606","name":"Almirall","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s13555-024-01252-7","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T19:01:56Z","timestamp":1724785316000},"page":"2645-2652","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A 3-Year Experience with Tildrakizumab Treatment for Patients with Plaque Psoriasis in Clinical Practice"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4381-6718","authenticated-orcid":false,"given":"Martina","family":"Burlando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0151-3126","authenticated-orcid":false,"given":"Ilaria","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Parodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Cozzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"1252_CR1","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40265-018-0917-3","volume":"78","author":"A Markham","year":"2018","unstructured":"Markham A. Tildrakizumab: first global approval. Drugs. 2018;78:845\u20139.","journal-title":"Drugs"},{"key":"1252_CR2","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","volume":"390","author":"K Reich","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390:276\u201388.","journal-title":"Lancet"},{"key":"1252_CR3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/bjd.19866","volume":"185","author":"D Thaci","year":"2021","unstructured":"Thaci D, Piaserico S, Warren RB, et al. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). Br J Dermatol. 2021;185:323\u201334.","journal-title":"Br J Dermatol"},{"key":"1252_CR4","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2021-2-6","author":"M Burlando","year":"2021","unstructured":"Burlando M, Castelli R, Cozzani E, Parodi A. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. Drugs Context. 2021. https:\/\/doi.org\/10.7573\/dic.2021-2-6.","journal-title":"Drugs Context."},{"key":"1252_CR5","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1111\/jdv.19468","volume":"37","author":"S Berenguer-Ruiz","year":"2023","unstructured":"Berenguer-Ruiz S, Aparicio-Dom\u00ednguez M, Herranz-Pinto P, et al. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. J Eur Acad Dermatol Venereol. 2023;37:2517\u201325.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1252_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/jdv.18572","volume":"37","author":"A Tsianakas","year":"2023","unstructured":"Tsianakas A, Schwichtenberg U, Pierchalla P, Hinz T, Diemert S, Korge B. Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: results from the non-interventional, prospective, multicentre study TILOT. J Eur Acad Dermatol Venereol. 2023;37:85\u201392.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1252_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/jdv.18594","volume":"37","author":"A Narcisi","year":"2023","unstructured":"Narcisi A, Valenti M, Gargiulo L, et al. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: a 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis). J Eur Acad Dermatol Venereol. 2023;37:93\u2013103.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1252_CR8","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/bjd.18232","volume":"182","author":"K Reich","year":"2020","unstructured":"Reich K, Warren RB, Iversen L, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol. 2020;182:605\u201317.","journal-title":"Br J Dermatol"},{"key":"1252_CR9","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.1111\/ijd.15840","volume":"61","author":"M Gal\u00e1n-Gutierrez","year":"2022","unstructured":"Gal\u00e1n-Gutierrez M, Rodriguez-Fernandez Freire L, Ruiz-Villaverde R. Tildrakizumab: short-term efficacy and safety in real clinical practice. Int J Dermatol. 2022;61:e355\u20137.","journal-title":"Int J Dermatol"},{"key":"1252_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/1744666X.2023.2250918","volume":"20","author":"L Rusi\u00f1ol","year":"2024","unstructured":"Rusi\u00f1ol L, Carmona-Rocha E, Puig L. Durability and long-term outcomes of biologic therapies in psoriasis. Expert Rev Clin Immunol. 2024;20:71\u201382.","journal-title":"Expert Rev Clin Immunol"},{"key":"1252_CR11","doi-asserted-by":"publisher","first-page":"adv00631","DOI":"10.2340\/actadv.v101.910","volume":"102","author":"T M\u00e4lk\u00f6nen","year":"2022","unstructured":"M\u00e4lk\u00f6nen T, Nuutinen P, Hallinen T, et al. Guselkumab treatment outcomes and persistence in a nationwide real-world cohort of patients with plaque psoriasis. Acta Derm Venereol. 2022;102:adv00631.","journal-title":"Acta Derm Venereol"},{"key":"1252_CR12","doi-asserted-by":"publisher","first-page":"15078","DOI":"10.1038\/s41598-022-18790-9","volume":"12","author":"T Graier","year":"2022","unstructured":"Graier T, Weger W, Jonak C, et al. Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian psoriasis registry (PsoRA). Sci Rep. 2022;12:15078.","journal-title":"Sci Rep"},{"key":"1252_CR13","first-page":"6772","volume":"26","author":"M Burlando","year":"2022","unstructured":"Burlando M, Maul JT, Salvi I, et al. Psoriasis patients\u2019 characteristics associated with high PASI response to tildrakizumab: an international dual center study. Eur Rev Med Pharmacol Sci. 2022;26:6772\u20136.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1252_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049822","volume":"11","author":"K Eyerich","year":"2021","unstructured":"Eyerich K, Weisenseel P, Pinter A, et al. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open. 2021;11: e049822.","journal-title":"BMJ Open"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01252-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01252-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01252-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T12:48:00Z","timestamp":1726145280000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01252-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1252"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01252-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]},"assertion":[{"value":"7 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M. Burlando, A. Parodi and E. Cozzani acted as speaker and consultant for Abbvie, Janssen, Amgen, Novartis, Eli Lilly, UCB Pharma. I. Salvi has no conflicting interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All subjects provided informed written consent prior to enrollment in the study. All procedures performed were in accordance with the 1964 Helsinki Declaration and its later amendments. The present study was approved by the ethics committee of Ospedale Policlinico San Martino-IRCCS, Genova, Italy (study number 163\/2023; protocol: Pubb_Pso_Burlando; Study ID: 10529). All subjects gave consent to participate. Participants gave consent to the publication of anonymous data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}